Manuela Grimstein

MedicinePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma”.

FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1272

N/A

1.4DataRank · unranked

35 citations

Yvette L. Kasamon, Justin S. Collazo, Ruby Leong, Kun Wang, P Li +8 more

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1086

N/A

0.385DataRank · unranked

12 citations

Edwin C.Y. Chow, Alexei Ionan, Haiyan Chen, Shwu‐Luan Lee, Vicky Hsu +10 more

Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development

Frontiers in Pediatrics(2021)10.3389/fped.2021.721059

N/A

0DataRank · unranked

11 citations

Mary Gockenbach, Manuela Grimstein, Hari Cheryl Sachs, Mark Mirochnick, Kimberly Struble +8 more

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0949

N/A

0DataRank · unranked

14 citations

Diana Bradford, Yi Ren, Stephanie Aungst, Claudia P. Miller, Lili Pan +19 more